Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
Appointed
Chong Set Fui (Angeline)
Chief Financial Officer and Principal Financial Officer
On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Su-Leng Tan Lee departed as acting Chief Financial Officer and Principal Financial Officer at BioNexus Gene Lab Corp.
Action
ceased
Role
acting Chief Financial Officer and Principal Financial Officer
Exact text from the filing
Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
Chong Set Fui (Angeline) was appointed as Chief Financial Officer and Principal Financial Officer at BioNexus Gene Lab Corp.
Action
appointed
Role
Chief Financial Officer and Principal Financial Officer
Exact text from the filing
On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.